VLP vaccines are a type of recombinant vaccine, but they offer the efficiency of a live-attenuated vaccine. Recombinant vaccines use a particular piece of the germ that the immune system targets specifically.
The global VLP Vaccines market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2029, growing at a CAGR of % during 2021-2029.
This report focuses on VLP Vaccines volume and value at the global level, regional level and company level. From a global perspective, this report represents overall VLP Vaccines market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global VLP Vaccines Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2029. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
HPV Vaccine
Covid-19 Vaccine
Hepatitis B Vaccine
Others
Segment by Application
Government
Medical Institution
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Medicago
Novavax
Saiba Animal Health
VBI
ARTES Biotechnology
VLP Therapeutics
POSVAX
Spybiotech
Optipharm Co. Ltd
H&Z Life Science
Gproan
Merck
1 VLP Vaccines Market Overview
1.1 Product Overview and Scope of VLP Vaccines
1.2 VLP Vaccines Segment by Type
1.2.1 Global VLP Vaccines Sales Growth Rate Comparison by Type (2021-2029)
1.2.2 HPV Vaccine
1.2.3 Covid-19 Vaccine
1.2.4 Hepatitis B Vaccine
1.2.5 Others
1.3 VLP Vaccines Segment by Application
1.3.1 Global VLP Vaccines Sales Comparison by Application: (2021-2029)
1.3.2 Government
1.3.3 Medical Institution
1.3.4 Others
1.4 Global VLP Vaccines Market Size Estimates and Forecasts
1.4.1 Global VLP Vaccines Revenue 2016-2029
1.4.2 Global VLP Vaccines Sales 2016-2029
1.4.3 VLP Vaccines Market Size by Region: 2016 Versus 2021 Versus 2029
2 VLP Vaccines Market Competition by Manufacturers
2.1 Global VLP Vaccines Sales Market Share by Manufacturers (2016-2021)
2.2 Global VLP Vaccines Revenue Market Share by Manufacturers (2016-2021)
2.3 Global VLP Vaccines Average Price by Manufacturers (2016-2021)
2.4 Manufacturers VLP Vaccines Manufacturing Sites, Area Served, Product Type
2.5 VLP Vaccines Market Competitive Situation and Trends
2.5.1 VLP Vaccines Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest VLP Vaccines Players Market Share by Revenue
2.5.3 Global VLP Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 VLP Vaccines Retrospective Market Scenario by Region
3.1 Global VLP Vaccines Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global VLP Vaccines Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America VLP Vaccines Market Facts & Figures by Country
3.3.1 North America VLP Vaccines Sales by Country
3.3.2 North America VLP Vaccines Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe VLP Vaccines Market Facts & Figures by Country
3.4.1 Europe VLP Vaccines Sales by Country
3.4.2 Europe VLP Vaccines Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific VLP Vaccines Market Facts & Figures by Region
3.5.1 Asia Pacific VLP Vaccines Sales by Region
3.5.2 Asia Pacific VLP Vaccines Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America VLP Vaccines Market Facts & Figures by Country
3.6.1 Latin America VLP Vaccines Sales by Country
3.6.2 Latin America VLP Vaccines Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa VLP Vaccines Market Facts & Figures by Country
3.7.1 Middle East and Africa VLP Vaccines Sales by Country
3.7.2 Middle East and Africa VLP Vaccines Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global VLP Vaccines Historic Market Analysis by Type
4.1 Global VLP Vaccines Sales Market Share by Type (2016-2021)
4.2 Global VLP Vaccines Revenue Market Share by Type (2016-2021)
4.3 Global VLP Vaccines Price by Type (2016-2021)
5 Global VLP Vaccines Historic Market Analysis by Application
5.1 Global VLP Vaccines Sales Market Share by Application (2016-2021)
5.2 Global VLP Vaccines Revenue Market Share by Application (2016-2021)
5.3 Global VLP Vaccines Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Medicago
6.1.1 Medicago Corporation Information
6.1.2 Medicago Description and Business Overview
6.1.3 Medicago VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Medicago VLP Vaccines Product Portfolio
6.1.5 Medicago Recent Developments/Updates
6.2 Novavax
6.2.1 Novavax Corporation Information
6.2.2 Novavax Description and Business Overview
6.2.3 Novavax VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Novavax VLP Vaccines Product Portfolio
6.2.5 Novavax Recent Developments/Updates
6.3 Saiba Animal Health
6.3.1 Saiba Animal Health Corporation Information
6.3.2 Saiba Animal Health Description and Business Overview
6.3.3 Saiba Animal Health VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Saiba Animal Health VLP Vaccines Product Portfolio
6.3.5 Saiba Animal Health Recent Developments/Updates
6.4 VBI
6.4.1 VBI Corporation Information
6.4.2 VBI Description and Business Overview
6.4.3 VBI VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.4.4 VBI VLP Vaccines Product Portfolio
6.4.5 VBI Recent Developments/Updates
6.5 ARTES Biotechnology
6.5.1 ARTES Biotechnology Corporation Information
6.5.2 ARTES Biotechnology Description and Business Overview
6.5.3 ARTES Biotechnology VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.5.4 ARTES Biotechnology VLP Vaccines Product Portfolio
6.5.5 ARTES Biotechnology Recent Developments/Updates
6.6 VLP Therapeutics
6.6.1 VLP Therapeutics Corporation Information
6.6.2 VLP Therapeutics Description and Business Overview
6.6.3 VLP Therapeutics VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.6.4 VLP Therapeutics VLP Vaccines Product Portfolio
6.6.5 VLP Therapeutics Recent Developments/Updates
6.7 POSVAX
6.6.1 POSVAX Corporation Information
6.6.2 POSVAX Description and Business Overview
6.6.3 POSVAX VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.4.4 POSVAX VLP Vaccines Product Portfolio
6.7.5 POSVAX Recent Developments/Updates
6.8 Spybiotech
6.8.1 Spybiotech Corporation Information
6.8.2 Spybiotech Description and Business Overview
6.8.3 Spybiotech VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Spybiotech VLP Vaccines Product Portfolio
6.8.5 Spybiotech Recent Developments/Updates
6.9 Optipharm Co. Ltd
6.9.1 Optipharm Co. Ltd Corporation Information
6.9.2 Optipharm Co. Ltd Description and Business Overview
6.9.3 Optipharm Co. Ltd VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Optipharm Co. Ltd VLP Vaccines Product Portfolio
6.9.5 Optipharm Co. Ltd Recent Developments/Updates
6.10 H&Z Life Science
6.10.1 H&Z Life Science Corporation Information
6.10.2 H&Z Life Science Description and Business Overview
6.10.3 H&Z Life Science VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.10.4 H&Z Life Science VLP Vaccines Product Portfolio
6.10.5 H&Z Life Science Recent Developments/Updates
6.11 Gproan
6.11.1 Gproan Corporation Information
6.11.2 Gproan VLP Vaccines Description and Business Overview
6.11.3 Gproan VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Gproan VLP Vaccines Product Portfolio
6.11.5 Gproan Recent Developments/Updates
6.12 Merck
6.12.1 Merck Corporation Information
6.12.2 Merck VLP Vaccines Description and Business Overview
6.12.3 Merck VLP Vaccines Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Merck VLP Vaccines Product Portfolio
6.12.5 Merck Recent Developments/Updates
7 VLP Vaccines Manufacturing Cost Analysis
7.1 VLP Vaccines Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of VLP Vaccines
7.4 VLP Vaccines Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 VLP Vaccines Distributors List
8.3 VLP Vaccines Customers
9 VLP Vaccines Market Dynamics
9.1 VLP Vaccines Industry Trends
9.2 VLP Vaccines Growth Drivers
9.3 VLP Vaccines Market Challenges
9.4 VLP Vaccines Market Restraints
10 Global Market Forecast
10.1 VLP Vaccines Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of VLP Vaccines by Type (2022-2029)
10.1.2 Global Forecasted Revenue of VLP Vaccines by Type (2022-2029)
10.2 VLP Vaccines Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of VLP Vaccines by Application (2022-2029)
10.2.2 Global Forecasted Revenue of VLP Vaccines by Application (2022-2029)
10.3 VLP Vaccines Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of VLP Vaccines by Region (2022-2029)
10.3.2 Global Forecasted Revenue of VLP Vaccines by Region (2022-2029)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global VLP Vaccines Sales (K Doses) Growth Rate Comparison by Type (2021-2029)
Table 2. Global VLP Vaccines Sales (K Doses) Comparison by Application (2021-2029)
Table 3. Global VLP Vaccines Market Size by Region (US$ Million) (2016 VS 2021 VS 2029)
Table 4. Key Manufacturers VLP Vaccines Covered in This Study
Table 5. Global VLP Vaccines Sales (K Doses) of Key Manufacturers (2016-2021)
Table 6. Global VLP Vaccines Sales Market Share by Manufacturers (2016-2021)
Table 7. Global VLP Vaccines Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global VLP Vaccines Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market VLP Vaccines Average Price (US$/Dose) of Key Manufacturers (2016-2021)
Table 10. Manufacturers VLP Vaccines Manufacturing Sites and Area Served
Table 11. Manufacturers VLP Vaccines Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global VLP Vaccines by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in VLP Vaccines as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global VLP Vaccines Sales by Region (2016-2021) & (K Doses)
Table 16. Global VLP Vaccines Sales Market Share by Region (2016-2021)
Table 17. Global VLP Vaccines Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America VLP Vaccines Sales by Country (2016-2021) & (K Doses)
Table 19. North America VLP Vaccines Sales Market Share by Country (2016-2021)
Table 20. North America VLP Vaccines Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America VLP Vaccines Revenue Market Share by Country (2016-2021)
Table 22. Europe VLP Vaccines Sales by Country (2016-2021) & (K Doses)
Table 23. Europe VLP Vaccines Sales Market Share by Country (2016-2021)
Table 24. Europe VLP Vaccines Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe VLP Vaccines Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific VLP Vaccines Sales by Region (2016-2021) & (K Doses)
Table 27. Asia Pacific VLP Vaccines Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific VLP Vaccines Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific VLP Vaccines Revenue Market Share by Region (2016-2021)
Table 30. Latin America VLP Vaccines Sales by Country (2016-2021) & (K Doses)
Table 31. Latin America VLP Vaccines Sales Market Share by Country (2016-2021)
Table 32. Latin America VLP Vaccines Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America VLP Vaccines Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa VLP Vaccines Sales by Country (2016-2021) & (K Doses)
Table 35. Middle East and Africa VLP Vaccines Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa VLP Vaccines Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa VLP Vaccines Revenue Market Share by Country (2016-2021)
Table 38. Global VLP Vaccines Sales (K Doses) by Type (2016-2021)
Table 39. Global VLP Vaccines Sales Market Share by Type (2016-2021)
Table 40. Global VLP Vaccines Revenue (Million US$) by Type (2016-2021)
Table 41. Global VLP Vaccines Revenue Share by Type (2016-2021)
Table 42. Global VLP Vaccines Price (US$/Dose) by Type (2016-2021)
Table 43. Global VLP Vaccines Sales (K Doses) by Application (2016-2021)
Table 44. Global VLP Vaccines Sales Market Share by Application (2016-2021)
Table 45. Global VLP Vaccines Revenue (Million US$) by Application (2016-2021)
Table 46. Global VLP Vaccines Revenue Share by Application (2016-2021)
Table 47. Global VLP Vaccines Price (US$/Dose) by Application (2016-2021)
Table 48. Medicago Corporation Information
Table 49. Medicago Description and Business Overview
Table 50. Medicago VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 51. Medicago VLP Vaccines Product
Table 52. Medicago Recent Developments/Updates
Table 53. Novavax Corporation Information
Table 54. Novavax Description and Business Overview
Table 55. Novavax VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 56. Novavax VLP Vaccines Product
Table 57. Novavax Recent Developments/Updates
Table 58. Saiba Animal Health Corporation Information
Table 59. Saiba Animal Health Description and Business Overview
Table 60. Saiba Animal Health VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 61. Saiba Animal Health VLP Vaccines Product
Table 62. Saiba Animal Health Recent Developments/Updates
Table 63. VBI Corporation Information
Table 64. VBI Description and Business Overview
Table 65. VBI VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 66. VBI VLP Vaccines Product
Table 67. VBI Recent Developments/Updates
Table 68. ARTES Biotechnology Corporation Information
Table 69. ARTES Biotechnology Description and Business Overview
Table 70. ARTES Biotechnology VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 71. ARTES Biotechnology VLP Vaccines Product
Table 72. ARTES Biotechnology Recent Developments/Updates
Table 73. VLP Therapeutics Corporation Information
Table 74. VLP Therapeutics Description and Business Overview
Table 75. VLP Therapeutics VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 76. VLP Therapeutics VLP Vaccines Product
Table 77. VLP Therapeutics Recent Developments/Updates
Table 78. POSVAX Corporation Information
Table 79. POSVAX Description and Business Overview
Table 80. POSVAX VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 81. POSVAX VLP Vaccines Product
Table 82. POSVAX Recent Developments/Updates
Table 83. Spybiotech Corporation Information
Table 84. Spybiotech Description and Business Overview
Table 85. Spybiotech VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 86. Spybiotech VLP Vaccines Product
Table 87. Spybiotech Recent Developments/Updates
Table 88. Optipharm Co. Ltd Corporation Information
Table 89. Optipharm Co. Ltd Description and Business Overview
Table 90. Optipharm Co. Ltd VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 91. Optipharm Co. Ltd VLP Vaccines Product
Table 92. Optipharm Co. Ltd Recent Developments/Updates
Table 93. H&Z Life Science Corporation Information
Table 94. H&Z Life Science Description and Business Overview
Table 95. H&Z Life Science VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 96. H&Z Life Science VLP Vaccines Product
Table 97. H&Z Life Science Recent Developments/Updates
Table 98. Gproan Corporation Information
Table 99. Gproan Description and Business Overview
Table 100. Gproan VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 101. Gproan VLP Vaccines Product
Table 102. Gproan Recent Developments/Updates
Table 103. Merck Corporation Information
Table 104. Merck Description and Business Overview
Table 105. Merck VLP Vaccines Sales (K Doses), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 106. Merck VLP Vaccines Product
Table 107. Merck Recent Developments/Updates
Table 108. Production Base and Market Concentration Rate of Raw Material
Table 109. Key Suppliers of Raw Materials
Table 110. VLP Vaccines Distributors List
Table 111. VLP Vaccines Customers List
Table 112. VLP Vaccines Market Trends
Table 113. VLP Vaccines Growth Drivers
Table 114. VLP Vaccines Market Challenges
Table 115. VLP Vaccines Market Restraints
Table 116. Global VLP Vaccines Sales Forecast by Type (2022-2029) & (K Doses)
Table 117. Global VLP Vaccines Sales Market Share Forecast by Type (2022-2029)
Table 118. Global VLP Vaccines Revenue Forecast by Type (2022-2029) & (US$ Million)
Table 119. Global VLP Vaccines Revenue Market Share Forecast by Type (2022-2029)
Table 120. Global VLP Vaccines Sales Forecast by Application (2022-2029) & (K Doses)
Table 121. Global VLP Vaccines Sales Market Share Forecast by Application (2022-2029)
Table 122. Global VLP Vaccines Revenue Forecast by Application (2022-2029) & (US$ Million)
Table 123. Global VLP Vaccines Revenue Market Share Forecast by Application (2022-2029)
Table 124. Global VLP Vaccines Sales Forecast by Region (2022-2029) & (K Doses)
Table 125. Global VLP Vaccines Sales Market Share Forecast by Region (2022-2029)
Table 126. Global VLP Vaccines Revenue Forecast by Region (2022-2029) & (US$ Million)
Table 127. Global VLP Vaccines Revenue Market Share Forecast by Region (2022-2029)
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of VLP Vaccines
Figure 2. Global VLP Vaccines Market Share by Type in 2020 & 2029
Figure 3. HPV Vaccine Product Picture
Figure 4. Covid-19 Vaccine Product Picture
Figure 5. Hepatitis B Vaccine Product Picture
Figure 6. Others Product Picture
Figure 7. Global VLP Vaccines Market Share by Application in 2020 & 2029
Figure 8. Government
Figure 9. Medical Institution
Figure 10. Others
Figure 11. Global VLP Vaccines Revenue, (US$ Million), 2016 VS 2021 VS 2029
Figure 12. Global VLP Vaccines Market Size 2016-2029 (US$ Million)
Figure 13. Global VLP Vaccines Sales 2016-2029 (K Doses)
Figure 14. Global VLP Vaccines Market Size Market Share by Region: 2016 VS 20210 VS 2029
Figure 15. VLP Vaccines Sales Share by Manufacturers in 2020
Figure 16. Global VLP Vaccines Revenue Share by Manufacturers in 2020
Figure 17. The Global 5 and 10 Largest VLP Vaccines Players: Market Share by Revenue in 2020
Figure 18. VLP Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 19. Global VLP Vaccines Sales Market Share by Region (2016-2021)
Figure 20. Global VLP Vaccines Sales Market Share by Region in 2020
Figure 21. Global VLP Vaccines Revenue Market Share by Region (2016-2021)
Figure 22. Global VLP Vaccines Revenue Market Share by Region in 2020
Figure 23. United States VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Canada VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Germany VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. France VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. U.K. VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Italy VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Russia VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. China VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Japan VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. South Korea VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. India VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Australia VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Taiwan VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Indonesia VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Thailand VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Malaysia VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Mexico VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Brazil VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Argentina VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Colombia VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Turkey VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Saudi Arabia VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. UAE VLP Vaccines Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Sales Market Share of VLP Vaccines by Type (2016-2021)
Figure 47. Sales Market Share of VLP Vaccines by Application (2016-2021)
Figure 48. Sales Market Share of VLP Vaccines by Application in 2020
Figure 49. Revenue Share of VLP Vaccines by Application (2016-2021)
Figure 50. Revenue Share of VLP Vaccines by Application in 2020
Figure 51. Manufacturing Cost Structure of VLP Vaccines
Figure 52. Manufacturing Process Analysis of VLP Vaccines
Figure 53. VLP Vaccines Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
The research methodology employed by VICResearch has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of VICResearch. VICResearch’s methodology can be divided into five stages:
Stage 1: Secondary research
The research team first works with magazines, industry trade group, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Stage 2: Primary research: interviews with trade sources
After the first stage, the research team conducts large number of face-to-face or telephone interviews with the representative companies operating in the research field. The analysts attempt to obtain a chance to talk with leading players in the field as well as with small companies. The upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers are all included in the interviews. The data gathered during the interview is then carefully checked and compared with the secondary research.
Stage 3: Analysis of the gathered data
The analysis team checks and synthesizes the data gathered during the first two stages. To validate the data, a second series of interviews can be conducted.
Stage 4: Quantitative data
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by VICResearch. The data is based on the estimates obtained during stage 3.
The research team also provides appreciation and analysis of the market and the quantitative data contained in the reports. The data is consequently unique to VICResearch.
Stage 5: Quality control
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the VICResearch’s internal quality process.
Consulting report: +86-15323335301 020-31521856
